Tempus AI, Inc. $TEM Stock Holdings Lifted by Washington Trust Advisors Inc.

Washington Trust Advisors Inc. grew its stake in shares of Tempus AI, Inc. (NASDAQ:TEM) by 49.1% in the second quarter, Holdings Channel.com reports. The fund owned 89,166 shares of the company’s stock after buying an additional 29,347 shares during the quarter. Washington Trust Advisors Inc.’s holdings in Tempus AI were worth $5,165,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Victory Capital Management Inc. grew its holdings in shares of Tempus AI by 1.5% in the 3rd quarter. Victory Capital Management Inc. now owns 11,078 shares of the company’s stock worth $894,000 after acquiring an additional 162 shares during the last quarter. Truist Financial Corp lifted its holdings in shares of Tempus AI by 5.8% during the fourth quarter. Truist Financial Corp now owns 3,532 shares of the company’s stock valued at $209,000 after purchasing an additional 194 shares during the last quarter. SeaCrest Wealth Management LLC boosted its position in shares of Tempus AI by 3.7% in the 3rd quarter. SeaCrest Wealth Management LLC now owns 6,488 shares of the company’s stock valued at $524,000 after purchasing an additional 229 shares during the period. Northwestern Mutual Wealth Management Co. boosted its position in shares of Tempus AI by 64.5% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 653 shares of the company’s stock valued at $53,000 after purchasing an additional 256 shares during the period. Finally, Pathstone Holdings LLC increased its stake in Tempus AI by 1.4% in the 3rd quarter. Pathstone Holdings LLC now owns 18,338 shares of the company’s stock worth $1,480,000 after purchasing an additional 261 shares in the last quarter. 24.22% of the stock is owned by institutional investors.

Tempus AI Price Performance

NASDAQ:TEM opened at $64.62 on Monday. The business’s fifty day moving average price is $55.77 and its 200 day moving average price is $52.13. The firm has a market capitalization of $11.66 billion, a price-to-earnings ratio of -44.87 and a beta of 3.72. The company has a current ratio of 3.30, a quick ratio of 3.16 and a debt-to-equity ratio of 3.06. Tempus AI, Inc. has a 1-year low of $40.77 and a 1-year high of $104.32.

Tempus AI (NASDAQ:TEM) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The firm had revenue of $382.49 million during the quarter, compared to analyst estimates of $379.69 million. During the same period last year, the company posted ($0.22) EPS. The business’s quarterly revenue was up 21.6% compared to the same quarter last year. On average, sell-side analysts forecast that Tempus AI, Inc. will post -1.38 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Ryan Fukushima sold 14,286 shares of the business’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $70.00, for a total transaction of $1,000,020.00. Following the transaction, the chief executive officer directly owned 47,420 shares of the company’s stock, valued at approximately $3,319,400. The trade was a 23.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Eric Lefkofsky sold 238,152 shares of the company’s stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $68.39, for a total transaction of $16,287,215.28. Following the completion of the transaction, the chief executive officer owned 161,848 shares in the company, valued at approximately $11,068,784.72. This represents a 59.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,043,988 shares of company stock valued at $56,963,417 over the last ninety days. Insiders own 24.26% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on TEM shares. Cantor Fitzgerald began coverage on Tempus AI in a report on Wednesday, September 2nd. They set an “overweight” rating and a $80.00 price objective on the stock. HC Wainwright dropped their target price on shares of Tempus AI from $64.00 to $56.00 and set a “buy” rating on the stock in a research report on Monday, August 3rd. TD Cowen reissued a “buy” rating on shares of Tempus AI in a research report on Wednesday, July 15th. Piper Sandler upgraded shares of Tempus AI from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $56.00 to $76.00 in a report on Tuesday, September 1st. Finally, Needham & Company LLC restated a “buy” rating and issued a $75.00 price target on shares of Tempus AI in a research report on Friday, July 31st. Eleven analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $68.93.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.